Please login to the form below

Not currently logged in
Email:
Password:

Aubagio

This page shows the latest Aubagio news and features for those working in and with pharma, biotech and healthcare.

J&J’s multiple sclerosis therapy Ponvory moves closer to EU approval

J&J’s multiple sclerosis therapy Ponvory moves closer to EU approval

s Aubagio (teriflunomide) in adult patients with RMS. ... Ponvory demonstrated superior efficacy on the primary endpoint – annualised relapse rate (ARR) – with a rate reduction of 30.5% compared to Aubagio.

Latest news

  • J&J’s MS drug ponesimod receives approval in the US J&J’s MS drug ponesimod receives approval in the US

    Data from that trial showed that treatment with Ponvory was associated with a statistically significant, 30.5% reduction in the annualised relapse rate (ARR) compared to Aubagio in patients with the ... Over the study period, 71% of Ponvory-treated

  • Novartis wins FDA approval for relapsing MS drug Kesimpta Novartis wins FDA approval for relapsing MS drug Kesimpta

    The approval is based on results from the phase 3 ASCLEPIOS I and II studies, in which Kesimpta (ofatumumab) demonstrated superiority over Sanofi’s Aubagio (teriflunomide) in reducing the number of ... However, the drug will have fierce competition in

  • Novartis builds its case for novel MS treatment ofatumumab Novartis builds its case for novel MS treatment ofatumumab

    The ASCLEPIOS I and II trials evaluated a subcutaneous injection of ofatumumab compared to Sanofi’s once-daily oral Aubagio (teriflunomide) pill in adults with relapsing multiple sclerosis (RMS). ... Ofatumumab outperformed Aubagio on both annualised

  • J&J aims for US approval of MS drug ponesimod J&J aims for US approval of MS drug ponesimod

    Data from that trial showed that treatment with ponesimod was associated with a statistically significant, 30.5% reduction in the annualised relapse rate (ARR) compared to Aubagio in patients with the ... J&J’s drug also outperformed Aubagio on fatigue

  • Sanofi highlights MS drug data as it swings to a loss in Q4 Sanofi highlights MS drug data as it swings to a loss in Q4

    For 2019 as a whole it topped 2.1bn in sales. Sanofi already has an established MS franchise with oral therapy Aubagio (teriflunomide) and Lemtrada (alemtuzumab), but that declined 3% to

More from news
Approximately 9 fully matching, plus 45 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Life Healthcare Communications

Life is a creative communications agency offering multi-channel solutions for the healthcare industry. We use a storytelling approach to turn...

Latest intelligence

How a design mindset can lead to better medical outcomes
By adopting a design philosophy, healthcare companies can develop communications that allow healthcare professionals (HCPs) to better meet the needs of their patients. Imaginatively designed content combined with patient insights...
How does the government plan to reshape the NHS?
Oli Hudson, of Wilmington Healthcare, explores the government’s new white paper, which proposes key reforms for health and social care...
Want to give perfect client service? Tough luck, you’re human
In this article an ex-client of mine, Liz Skrbkova, and I explore the (unhelpful) pressures of trying to perfect the client-agency relationship...

Infographics